Autolus director files initial insider holdings

Autolus Therapeutics plc director Martin Anton Pule filed an initial insider ownership report listing his existing equity interests in the company.

Rhea-AI Filing Summary

Autolus Therapeutics plc director Martin Anton Pule filed an initial insider ownership report listing his existing equity interests in the company. The filing shows multiple share option awards over American Depositary Shares with exercise prices from $0.001 to $30.29 and expiration dates extending through 2036.

He also reports 50,000 restricted share units that vest in four equal annual installments starting on January 26, 2027, with each unit convertible into one American Depositary Share. In addition, he holds 70,000 American Depositary Shares directly. The filing records holdings only and does not reflect new market purchases or sales.

Insider Trade Summary

13 transactions reported

Mixed 13 txns

Insider Pule Martin Anton

Role Director

Type	Security	Shares	Price	Value
holding	Share Option (right to buy)	--	--	--
holding	Share Option (right to buy)	--	--	--
holding	Share Option (right to buy)	--	--	--
holding	Share Option (right to buy)	--	--	--
holding	Share Option (right to buy)	--	--	--
holding	Share Option (right to buy)	--	--	--
holding	Share Option (right to buy)	--	--	--
holding	Share Option (right to buy)	--	--	--
holding	Share Option (right to buy)	--	--	--
holding	Share Option (right to buy)	--	--	--
holding	Share Option (right to buy)	--	--	--
holding	Restricted Share Units	--	--	--
holding	American Depositary Shares	--	--	--

Holdings After Transaction: Share Option (right to buy) — 1,318,262 contracts (Direct); Restricted Share Units — 50,000 contracts (Direct); American Depositary Shares — 70,000 contracts (Direct)

Footnotes (8)

1. F1. Fully vested and exercisable.
2. F2. This option vested 25% on July 22, 2023 and the remainder vests in 36 equal monthly installments thereafter.
3. F3. This option vested 25% on March 6, 2024 and the remainder vests in 36 equal monthly installments thereafter.
4. F4. This option vests 25% on October 12, 2024 and the remainder vests in 36 equal monthly installments thereafter.
5. F5. This option vests 25% on March 14, 2026 and the remainder vests in 36 equal monthly installments thereafter.
6. F6. This option vests 25% on January 26, 2027 and the remainder vests in 36 equal monthly installments thereafter.
7. F7. The restricted share units ("RSUs") vest in four equal annual installments commencing on January 26, 2027.
8. F8. Each RSU represents a contingent right to receive one Issuer American Depositary Share.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Autolus Therapeutics (AUTL) Form 3 filing disclose?

The Form 3 discloses director Martin Anton Pule’s existing equity holdings in Autolus Therapeutics. It lists multiple option grants, 50,000 restricted share units, and 70,000 American Depositary Shares, providing a baseline of his ownership at the time of becoming a reporting insider.

Did Martin Anton Pule buy or sell Autolus (AUTL) shares in this Form 3?

No, the Form 3 records holdings only, not new trades. It reports previously granted share options, restricted share units, and American Depositary Shares, establishing his starting ownership position as a director rather than documenting fresh market purchases or sales.

What stock options does Martin Anton Pule hold in Autolus (AUTL)?

He holds several option awards over American Depositary Shares with exercise prices ranging from $0.001 to $30.29 and expirations running from 2027 through 2036. Each award covers a specific number of underlying shares, reflecting long-term, equity-based compensation grants.

How do the restricted share units in the Autolus (AUTL) Form 3 vest?

The filing shows 50,000 restricted share units vesting in four equal annual installments starting January 26, 2027. Each vested unit converts into one American Depositary Share, spreading additional share delivery to the director over several years, subject to continued service conditions.

How many Autolus (AUTL) American Depositary Shares does Martin Anton Pule already hold?

The Form 3 indicates direct ownership of 70,000 American Depositary Shares. This position sits alongside his various option grants and restricted share units, giving him a mix of current equity exposure and additional potential future shares through long-dated awards.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/18/2026 - 07:49 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Pule Martin Anton

(Last) (First) (Middle)

C/O AUTOLUS THERAPEUTICS PLC

THE MEDIAWORKS, 191 WOOD LN, WHITE CITY

(Street)

LONDON W12 7FP

(City) (State) (Zip)

UNITED KINGDOM

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Autolus Therapeutics plc [ AUTL ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (right to buy)	(1)	04/21/2027	American Depositary Shares	34,306	$0.001	D
Share Option (right to buy)	(1)	02/06/2028	American Depositary Shares	43,956	$8.38	D
Share Option (right to buy)	(1)	12/18/2028	American Depositary Shares	25,000	$30.29	D
Share Option (right to buy)	(1)	12/13/2029	American Depositary Shares	90,000	$12.65	D
Share Option (right to buy)	(1)	12/15/2031	American Depositary Shares	100,000	$5.64	D
Share Option (right to buy)	(1)	12/15/2031	American Depositary Shares	75,000	$5.64	D
Share Option (right to buy)	(2)	07/22/2032	American Depositary Shares	125,000	$2.86	D
Share Option (right to buy)	(3)	03/06/2033	American Depositary Shares	150,000	$1.91	D
Share Option (right to buy)	(4)	10/12/2033	American Depositary Shares	150,000	$2.31	D
Share Option (right to buy)	(5)	03/14/2035	American Depositary Shares	300,000	$1.89	D
Share Option (right to buy)	(6)	01/26/2036	American Depositary Shares	225,000	$1.46	D
Restricted Share Units	(7)	(7)	American Depositary Shares	50,000	(8)	D
American Depositary Shares	(1)	01/15/2031	American Depositary Shares	70,000	$9.02	D

Explanation of Responses:

1. Fully vested and exercisable.

2. This option vested 25% on July 22, 2023 and the remainder vests in 36 equal monthly installments thereafter.

3. This option vested 25% on March 6, 2024 and the remainder vests in 36 equal monthly installments thereafter.

4. This option vests 25% on October 12, 2024 and the remainder vests in 36 equal monthly installments thereafter.

5. This option vests 25% on March 14, 2026 and the remainder vests in 36 equal monthly installments thereafter.

6. This option vests 25% on January 26, 2027 and the remainder vests in 36 equal monthly installments thereafter.

7. The restricted share units ("RSUs") vest in four equal annual installments commencing on January 26, 2027.

8. Each RSU represents a contingent right to receive one Issuer American Depositary Share.

	/s/ Martin Pule	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)